385 related articles for article (PubMed ID: 15168015)
1. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness.
Carey AL; Bruce CR; Sacchetti M; Anderson MJ; Olsen DB; Saltin B; Hawley JA; Febbraio MA
Diabetologia; 2004 Jun; 47(6):1029-37. PubMed ID: 15168015
[TBL] [Abstract][Full Text] [Related]
2. Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans.
Krogh-Madsen R; Plomgaard P; Møller K; Mittendorfer B; Pedersen BK
Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E108-14. PubMed ID: 16464907
[TBL] [Abstract][Full Text] [Related]
3. Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index.
Ruge T; Lockton JA; Renstrom F; Lystig T; Sukonina V; Svensson MK; Eriksson JW
Metabolism; 2009 Jun; 58(6):860-6. PubMed ID: 19375766
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous adipose tissue expression of tumour necrosis factor-alpha is not associated with whole body insulin resistance in obese nondiabetic or in type-2 diabetic subjects.
Koistinen HA; Bastard JP; Dusserre E; Ebeling P; Zegari N; Andreelli F; Jardel C; Donner M; Meyer L; Moulin P; Hainque B; Riou JP; Laville M; Koivisto VA; Vidal H
Eur J Clin Invest; 2000 Apr; 30(4):302-10. PubMed ID: 10759878
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance and increased muscle cytokine levels in patients with mitochondrial myopathy.
Rue N; Vissing J; Galbo H
J Clin Endocrinol Metab; 2014 Oct; 99(10):3757-65. PubMed ID: 25057876
[TBL] [Abstract][Full Text] [Related]
6. Skeletal muscle interleukin-6 and tumor necrosis factor-alpha release in healthy subjects and patients with type 2 diabetes at rest and during exercise.
Febbraio MA; Steensberg A; Starkie RL; McConell GK; Kingwell BA
Metabolism; 2003 Jul; 52(7):939-44. PubMed ID: 12870175
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor alpha and insulin resistance in obese type 2 diabetic patients.
Miyazaki Y; Pipek R; Mandarino LJ; DeFronzo RA
Int J Obes Relat Metab Disord; 2003 Jan; 27(1):88-94. PubMed ID: 12532159
[TBL] [Abstract][Full Text] [Related]
8. Hyperbaric oxygen therapy increases insulin sensitivity in overweight men with and without type 2 diabetes.
Wilkinson D; Nolting M; Mahadi MK; Chapman I; Heilbronn L
Diving Hyperb Med; 2015 Mar; 45(1):30-6. PubMed ID: 25964036
[TBL] [Abstract][Full Text] [Related]
9. Associations between insulin resistance and TNF-alpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes.
Plomgaard P; Nielsen AR; Fischer CP; Mortensen OH; Broholm C; Penkowa M; Krogh-Madsen R; Erikstrup C; Lindegaard B; Petersen AM; Taudorf S; Pedersen BK
Diabetologia; 2007 Dec; 50(12):2562-71. PubMed ID: 17928988
[TBL] [Abstract][Full Text] [Related]
10. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.
Kern PA; Ranganathan S; Li C; Wood L; Ranganathan G
Am J Physiol Endocrinol Metab; 2001 May; 280(5):E745-51. PubMed ID: 11287357
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines.
He G; Andersen O; Haugaard SB; Lihn AS; Pedersen SB; Madsbad S; Richelsen B
Eur J Clin Invest; 2005 Sep; 35(9):583-90. PubMed ID: 16128865
[TBL] [Abstract][Full Text] [Related]
12. Skeletal muscle triglycerides lowering is associated with net improvement of insulin sensitivity, TNF-alpha reduction and GLUT4 expression enhancement.
Mingrone G; Rosa G; Di Rocco P; Manco M; Capristo E; Castagneto M; Vettor R; Gasbarrini G; Greco AV
Int J Obes Relat Metab Disord; 2002 Sep; 26(9):1165-72. PubMed ID: 12187392
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance, endocrine function and adipokines in type 2 diabetes patients at different glycaemic levels: potential impact for glucotoxicity in vivo.
Lindmark S; Burén J; Eriksson JW
Clin Endocrinol (Oxf); 2006 Sep; 65(3):301-9. PubMed ID: 16918948
[TBL] [Abstract][Full Text] [Related]
14. Insulin stimulates interleukin-6 and tumor necrosis factor-alpha gene expression in human subcutaneous adipose tissue.
Krogh-Madsen R; Plomgaard P; Keller P; Keller C; Pedersen BK
Am J Physiol Endocrinol Metab; 2004 Feb; 286(2):E234-8. PubMed ID: 14532168
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 gene expression is increased in insulin-resistant rat skeletal muscle following insulin stimulation.
Carey AL; Lamont B; Andrikopoulos S; Koukoulas I; Proietto J; Febbraio MA
Biochem Biophys Res Commun; 2003 Mar; 302(4):837-40. PubMed ID: 12646246
[TBL] [Abstract][Full Text] [Related]
16. Discordant gene expression in skeletal muscle and adipose tissue of patients with type 2 diabetes: effect of interleukin-6 infusion.
Carey AL; Petersen EW; Bruce CR; Southgate RJ; Pilegaard H; Hawley JA; Pedersen BK; Febbraio MA
Diabetologia; 2006 May; 49(5):1000-7. PubMed ID: 16538490
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes.
Samaras K; Botelho NK; Chisholm DJ; Lord RV
Obesity (Silver Spring); 2010 May; 18(5):884-9. PubMed ID: 20019678
[TBL] [Abstract][Full Text] [Related]
18. Disassociation of muscle triglyceride content and insulin sensitivity after exercise training in patients with Type 2 diabetes.
Bruce CR; Kriketos AD; Cooney GJ; Hawley JA
Diabetologia; 2004 Jan; 47(1):23-30. PubMed ID: 14673522
[TBL] [Abstract][Full Text] [Related]
19. Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats.
Rotter Sopasakis V; Larsson BM; Johansson A; Holmäng A; Smith U
Diabetologia; 2004 Nov; 47(11):1879-87. PubMed ID: 15551046
[TBL] [Abstract][Full Text] [Related]
20. Increments in insulin sensitivity during intensive treatment are closely correlated with decrements in glucocorticoid receptor mRNA in skeletal muscle from patients with Type II diabetes.
Vestergaard H; Bratholm P; Christensen NJ
Clin Sci (Lond); 2001 Nov; 101(5):533-40. PubMed ID: 11672459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
